Shots:
Merck has reported the P-IIb/III (BRUNELLO) trial data assessing remigromig (MK-3000; 0.5 & 0.8mg, IVT, Q4W) vs ranibizumab (0.5mg, Q4W) in 984 adults with diabetic macular edema (DME)
In the trial, both remigromig doses met the 1EP, showing non-inferiority at 1yr. BCVA gains were +9.1 & +8.7 letters with 0.5 & 0.8mg, respectively, vs…
